BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:BIO3 • DE0005227235

30 EUR
0 (0%)
Last: May 23, 2025, 01:53 PM
Fundamental Rating

4

BIO3 gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 84 industry peers in the Biotechnology industry. BIO3 has only an average score on both its financial health and profitability. BIO3 has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year BIO3 has reported negative net income.
  • BIO3 had a positive operating cash flow in the past year.
  • In multiple years BIO3 reported negative net income over the last 5 years.
  • In multiple years BIO3 reported negative operating cash flow during the last 5 years.
BIO3.DE Yearly Net Income VS EBIT VS OCF VS FCFBIO3.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -1.73%, BIO3 is in the better half of the industry, outperforming 68.49% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -4.81%, BIO3 is in the better half of the industry, outperforming 69.86% of the companies in the same industry.
  • The Return On Invested Capital of BIO3 (0.54%) is better than 76.71% of its industry peers.
Industry RankSector Rank
ROA -1.73%
ROE -4.81%
ROIC 0.54%
ROA(3y)2.71%
ROA(5y)-0.12%
ROE(3y)7.23%
ROE(5y)-0.54%
ROIC(3y)N/A
ROIC(5y)N/A
BIO3.DE Yearly ROA, ROE, ROICBIO3.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30

1.3 Margins

  • With a decent Operating Margin value of 1.87%, BIO3 is doing good in the industry, outperforming 76.71% of the companies in the same industry.
  • BIO3's Operating Margin has improved in the last couple of years.
  • The Gross Margin of BIO3 (23.19%) is comparable to the rest of the industry.
  • BIO3's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 1.87%
PM (TTM) N/A
GM 23.19%
OM growth 3YN/A
OM growth 5Y99.04%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.34%
GM growth 5Y0.06%
BIO3.DE Yearly Profit, Operating, Gross MarginsBIO3.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIO3 is destroying value.
  • Compared to 1 year ago, BIO3 has about the same amount of shares outstanding.
  • The number of shares outstanding for BIO3 remains at a similar level compared to 5 years ago.
  • BIO3 has a better debt/assets ratio than last year.
BIO3.DE Yearly Shares OutstandingBIO3.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
BIO3.DE Yearly Total Debt VS Total AssetsBIO3.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

  • BIO3 has an Altman-Z score of 2.04. This is not the best score and indicates that BIO3 is in the grey zone with still only limited risk for bankruptcy at the moment.
  • BIO3's Altman-Z score of 2.04 is fine compared to the rest of the industry. BIO3 outperforms 65.75% of its industry peers.
  • BIO3 has a debt to FCF ratio of 46.44. This is a negative value and a sign of low solvency as BIO3 would need 46.44 years to pay back of all of its debts.
  • The Debt to FCF ratio of BIO3 (46.44) is better than 78.08% of its industry peers.
  • A Debt/Equity ratio of 1.26 is on the high side and indicates that BIO3 has dependencies on debt financing.
  • BIO3's Debt to Equity ratio of 1.26 is on the low side compared to the rest of the industry. BIO3 is outperformed by 60.27% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF 46.44
Altman-Z 2.04
ROIC/WACC0.09
WACC5.93%
BIO3.DE Yearly LT Debt VS Equity VS FCFBIO3.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 4.93 indicates that BIO3 has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 4.93, BIO3 is in the better half of the industry, outperforming 79.45% of the companies in the same industry.
  • BIO3 has a Quick Ratio of 1.66. This is a normal value and indicates that BIO3 is financially healthy and should not expect problems in meeting its short term obligations.
  • BIO3's Quick ratio of 1.66 is in line compared to the rest of the industry. BIO3 outperforms 46.58% of its industry peers.
Industry RankSector Rank
Current Ratio 4.93
Quick Ratio 1.66
BIO3.DE Yearly Current Assets VS Current LiabilitesBIO3.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The earnings per share for BIO3 have decreased strongly by -117.24% in the last year.
  • Looking at the last year, BIO3 shows a very negative growth in Revenue. The Revenue has decreased by -15.85% in the last year.
  • Measured over the past years, BIO3 shows a quite strong growth in Revenue. The Revenue has been growing by 11.62% on average per year.
EPS 1Y (TTM)-117.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-173.33%
Revenue 1Y (TTM)-15.85%
Revenue growth 3Y12.09%
Revenue growth 5Y11.62%
Sales Q2Q%-42.29%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y1600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BIO3.DE Yearly Revenue VS EstimatesBIO3.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
BIO3.DE Yearly EPS VS EstimatesBIO3.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2020 2021 2022 2024 2025 0 1 -1

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BIO3. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 19.80, which indicates a rather expensive current valuation of BIO3.
  • BIO3's Price/Forward Earnings ratio is rather cheap when compared to the industry. BIO3 is cheaper than 86.30% of the companies in the same industry.
  • BIO3's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.50.
Industry RankSector Rank
PE N/A
Fwd PE 19.8
BIO3.DE Price Earnings VS Forward Price EarningsBIO3.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BIO3 indicates a somewhat cheap valuation: BIO3 is cheaper than 75.34% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, BIO3 is valued a bit cheaper than the industry average as 79.45% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 82.44
EV/EBITDA 33.87
BIO3.DE Per share dataBIO3.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • BIO3's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • BIO3 has a yearly dividend return of 0.09%, which is pretty low.
  • Compared to an average industry Dividend Yield of 0.66, BIO3 pays a better dividend. On top of this BIO3 pays more dividend than 90.41% of the companies listed in the same industry.
  • With a Dividend Yield of 0.09, BIO3 pays less dividend than the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 0.09%

5.2 History

  • The dividend of BIO3 is nicely growing with an annual growth rate of 14.87%!
Dividend Growth(5Y)14.87%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • The dividend of BIO3 is growing, but earnings are growing more, so the dividend growth is sustainable.
DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
BIO3.DE Yearly Income VS Free CF VS DividendBIO3.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOTEST AG-VORZUGSAKTIEN

FRA:BIO3 (5/23/2025, 1:53:46 PM)

30

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12
Earnings (Next)08-04
Inst Owners0.21%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.19B
Revenue(TTM)635.20M
Net Income(TTM)-24.50M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.09%
Yearly Dividend0.04
Dividend Growth(5Y)14.87%
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 19.8
P/S 1.87
P/FCF 82.44
P/OCF 82.44
P/B 2.33
P/tB 2.41
EV/EBITDA 33.87
EPS(TTM)-0.65
EYN/A
EPS(NY)1.52
Fwd EY5.05%
FCF(TTM)0.36
FCFY1.21%
OCF(TTM)0.36
OCFY1.21%
SpS16.05
BVpS12.88
TBVpS12.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1.73%
ROE -4.81%
ROCE 0.95%
ROIC 0.54%
ROICexc 0.56%
ROICexgc 0.57%
OM 1.87%
PM (TTM) N/A
GM 23.19%
FCFM 2.27%
ROA(3y)2.71%
ROA(5y)-0.12%
ROE(3y)7.23%
ROE(5y)-0.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y111.24%
ROICexc growth 3YN/A
ROICexc growth 5Y111.29%
OM growth 3YN/A
OM growth 5Y99.04%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.34%
GM growth 5Y0.06%
F-Score3
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF 46.44
Debt/EBITDA 12.19
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 0.82
Cash Conversion 27.43%
Profit Quality N/A
Current Ratio 4.93
Quick Ratio 1.66
Altman-Z 2.04
F-Score3
WACC5.93%
ROIC/WACC0.09
Cap/Depr(3y)81.86%
Cap/Depr(5y)79.06%
Cap/Sales(3y)4.84%
Cap/Sales(5y)4.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-117.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-173.33%
EPS Next Y1600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-15.85%
Revenue growth 3Y12.09%
Revenue growth 5Y11.62%
Sales Q2Q%-42.29%
Revenue Next Year11.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-93.3%
EBIT growth 3YN/A
EBIT growth 5Y122.17%
EBIT Next Year825%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y114.72%
FCF growth 3Y27.05%
FCF growth 5YN/A
OCF growth 1Y114.72%
OCF growth 3Y21.56%
OCF growth 5YN/A

BIOTEST AG-VORZUGSAKTIEN / BIO3.DE FAQ

What is the ChartMill fundamental rating of BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) stock?

ChartMill assigns a fundamental rating of 4 / 10 to BIO3.DE.


Can you provide the valuation status for BIOTEST AG-VORZUGSAKTIEN?

ChartMill assigns a valuation rating of 4 / 10 to BIOTEST AG-VORZUGSAKTIEN (BIO3.DE). This can be considered as Fairly Valued.


How profitable is BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) stock?

BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) has a profitability rating of 4 / 10.


What is the financial health of BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) stock?

The financial health rating of BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) is 5 / 10.